业绩还未摆困的海王生物，卖身广东国资失败

Core Viewpoint - Haiwang Bio has faced continuous losses in 2023 and 2024, leading to the failure of its control transfer plan after three years of efforts [1][3]. Group 1: Control Transfer and Corporate Strategy - Haiwang Bio announced the termination of its control transfer and stock issuance to specific entities, which was intended to change its actual controller to the Guangdong Provincial Government [1]. - The company will continue to seek new cooperation partners among state-owned enterprises for equity cooperation and explore new development opportunities through resource integration and business collaboration [2]. Group 2: Financial Performance and Challenges - Haiwang Bio's net profit attributable to shareholders has shown consecutive losses of 1.69 billion yuan in 2023 and 1.193 billion yuan in 2024 [3]. - In Q1 2025, the company's net profit attributable to shareholders was 25 million yuan, a year-on-year decline of 44.38%, with a net loss of 74.74 million yuan after excluding non-recurring gains and losses [3]. - The company's accounts receivable reached 15.367 billion yuan, more than double its operating revenue, and its debt-to-asset ratio stood at 89.76%, the highest in the A-share pharmaceutical distribution sector [3].